Inclusion Criteria:

          -  Patients must be newly diagnosed with a clinical diagnosis of APL (initially by
             morphology of bone marrow or peripheral blood)

               -  Bone marrow is highly preferred but in cases where marrow cannot be obtained at
                  diagnosis, peripheral blood will be accepted

          -  If the RQ-PCR results are known at the time of study enrollment, the patient must
             demonstrate the PML-RARalpha transcript by RQ-PCR to be eligible

          -  NOTE: A lumbar puncture is not required in order to be enrolled on study nor are
             lumbar punctures recommended at the time of diagnosis; if the diagnosis of APL is
             known or suspected, diagnostic lumbar punctures in patients with neurologic symptoms
             should be deferred until any coagulopathy is corrected; if central nervous system
             (CNS) disease is suspected or proven, a computed tomography (CT) or magnetic resonance
             imaging (MRI) should be considered to rule out the possibility of an associated
             chloroma; if CNS disease is documented, patients are still eligible and will receive
             protocol directed intrathecal treatments

          -  Patients may receive up to a maximum of 5 days of pre-treatment with ATRA prior to
             administration of protocol therapy

          -  Treatment with hydroxyurea, corticosteroids (any route) and intrathecal cytarabine
             prior to beginning protocol directed therapy is allowed; however, it should be noted
             that lumbar puncture and intrathecal therapy at initial diagnosis of APL is not
             recommended

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Patients with secondary APL are excluded; this includes all patients with APL that may
             have resulted from prior treatment (chemotherapy or radiation)

          -  Patients with isolated myeloid sarcoma (myeloblastoma, chloroma, including leukemia
             cutis) but without evidence of APL by bone marrow or peripheral blood morphology are
             excluded

          -  Patients with a pre-existing diagnosis of a prolonged QT syndrome (even if corrected
             QT interval [QTc] is normal at the time of APL diagnosis) are excluded

          -  Patients with a baseline QTc of > 450 msec are excluded; Bazett's formula is to be
             used for measurement of the corrected QT interval: the QT interval (msec) divided by
             the square root of the RR interval (msec)

          -  Patients with a history or presence of significant ventricular or atrial
             tachyarrhythmia are excluded

          -  Patients with right bundle branch block plus left anterior hemiblock, bifascicular
             block are excluded

          -  Patients with serum creatinine > 3.0 mg/dL and patients on active dialysis for renal
             dysfunction are excluded

          -  Patients who have received treatment with any other cytotoxic chemotherapy prior to
             beginning protocol therapy (other than allowed in above criteria) are excluded

          -  Female patients who are pregnant are excluded; patients should not be pregnant or plan
             to become pregnant while on treatment; a pregnancy test prior to enrollment is
             required for female patients of childbearing potential

          -  Lactating females who plan to breastfeed their infants are excluded

          -  Sexually active patients of reproductive potential who have not agreed to be abstinent
             or use 2 forms of effective contraception during treatment through 1 month off therapy
             are excluded